NEW DELHI : US pharma giants Pfizer and Moderna would not have got approval for their COVID-19 vaccines had they conducted phase-three clinical trials during the second coronavirus wave which was driven by the Delta variant, Krishna Ella, Chairman and Managing Director of Bharat Biotech said on Wednesday.
Hyderabad-based Bharat Biotech, the manufacturer of COVID-19 Covaxin, said the efficacy of its vaccine would have been 85% against the original strain of the virus -- the one that was first detected in China. “I am telling you honestly.
If Pfizer and Moderna (would) have done a phase-three clinical trial during the second wave, they would not have got the license for the product," Ella said at an event organised by the Technology